Sign Out
Cartridge: Biphasic Isophane Insulin (70% Isophane Insulin/30% Soluble Insulin) (Humulin 70/30) is a premixed suspension of rapid and intermediate acting insulin.
Vial: Insulin Human (rDNA) is a premixed suspension of intermediate and rapid acting insulin.
KwikPen: Insulin Human (Humulin 70/30 KwikPen) is an intermediate-acting insulin preparation.
Pharmacology: Pharmacodynamics: The prime activity of insulin is the regulation of glucose metabolism.
In addition, insulin has several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
The typical activity profile (glucose utilization curve) following subcutaneous injection is illustrated as follows by the heavy line. Variations that a patient may experience in timing and/or intensity of insulin activity are illustrated by the shaded area. Individual variability will depend on factors such as size of dose, site of injection temperature and physical activity of the patient.
Cartridge: See Figure 1.
Click on icon to see table/diagram/imageVial: See Figure 2.
Click on icon to see table/diagram/imageKwikPen: See Figure 3.
Click on icon to see table/diagram/imagePharmacokinetics: The pharmacokinetics of insulin do not reflect the metabolic action of that hormone. Therefore, it is more appropriate to examine glucose utilization curves (as discussed previously) when considering the activity of insulin.
Toxicology: Preclinical safety data: Humulin is human insulin produced by recombinant technology. No serious events have been reported in subchronic toxicology studies. Human insulin was not mutagenic in a series of in vitro and in vivo genetic toxicity assays.
Continue with Google